On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...
Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the ...
JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's ...
Industry leaders explored the risks and benefits of adopting a China Plus One strategy at Advamed’s The MedTech Conference in ...
Johnson & Johnson beat investors’ expectations despite its medtech unit underperforming, with execs pointing to the Asia-Pacific region as a continued source of struggle. Executives said on the ...
Employees at the 10 largest medtech employers in the world are excited about culture but are still frustrated by corporate ...
MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%. The company’s non-MedTech operations are ...
Nodenza Venture Partners launchedFocus on international early-stage and pre-commercial biotech & medtech opportunitiesNew York, October 16, ...
Authors:Kirk Harmon, Vice President & GM, Contract Sales Organization, IQVIAJavier “Jave” Castillo, R.Ph, Vice President, CSO ...
The Infor Cloverleaf Data Integration Platform is now interoperable with the Nvidia Holoscan AI platform, providing more AI ...
Event puts focus on medical technologies Oct. 15-17 at the Metro Toronto Convention Centre ...
TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback